This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research focused on the inception and early-stage development of highly innovative molecular or cellular analysis technologies for basic and clinical cancer research. The emphasis of this FOA is on supporting the development of novel molecular and cellular analysis capabilities with a high degree of technical innovation with the potential to significantly affect and transform investigations exploring the molecular and cellular basis of cancer. If successful, these technologies should accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, and/or cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be based on molecular and/or cellular characterizations of cancer.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
This FOA utilizes the R21 award mechanism for exploratory/developmental projects. The R21 mechanism is suitable for projects that are at their inception, conceptual, or idea-based phase. In this phase, technical feasibility of the proposed technology or methodology may not yet have been established. Preliminary data are not required, but are accepted if available. If preliminary data are sufficient to suggest the feasibility of the approach is established, then consideration should be given to submitting to the companion R33 FOA (RFA-CA-15-003).
For more information, please visit: